Semaphorin-3A and Netrin-1 predict the development of kidney injury in children with congenital hydronephrosis

Abstract

Congenital obstructive nephropathy is amongst the main causes of chronic renal failure in children. Early diagnosis and initiation of the treatment will delay progressive renal tubular atrophy and interstitial fibrosis with the loss of nephrons. The aim of this study was to evaluate whether urinary (u) semaphorin-3A (SEMA-3A) and Netrin-1 may be potential biomarkers in children with congenital hydronephrosis due to ureteropelvic junction obstruction (UPJO). The study consisted of 42 children with severe hydronephrosis who needed surgery and two control groups (Control One: 42 children with mild, non-obstructive hydronephrosis; Control Two: 44 healthy children). All children had normal renal function. Urinary semaphorin-3A and Netrin-1 levels were measured in different groups using immunoenzymatic ELISA commercial kits. Compared with Control One and Control Two groups, the preoperative median uSEMA-3A/creatinine (cr.) and uNetrin-1/cr. levels increased significantly in the children with severe hydronephrosis (p < .01). One month after surgery, uSEMA-3A/cr. and uNetrin-1/cr. levels had decreased significantly in the children with severe hydronephrosis (p < .01), but were still higher than those in both control groups (p < .05). Receiver operator characteristic (ROC) analyses revealed a good diagnostic profile for uSEMA-3A and uNetrin-1 in terms of identifying children with a differential renal function of <40% [area under the curve (AUC) 0.825 and 0.745, respectively]. Our results indicate that increased concentrations of uSEMA-3A and uNetrin-1 are found in urine from children with severe hydronephrosis and that their concentrations are related to the degree of obstruction.

Keywords:

• Semaphorin-3A
• Netrin-1
• ureteropelvic junction obstruction
• biomarker
• urinary

Acknowledgments

This study was supported by ‘The National Nature Science Foundation of China (Grant No U1304803)’ and ‘The National Nature Science Foundation of China (Grant No. 81603527)’. The study was partly funded by ‘The Youth Innovation Fund of the First Affiliated Hospital of Zhengzhou University’.

Disclosure statement

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Funding

This study was supported by ‘The National Nature Science Foundation of China (Grant No U1304803)’ and ‘The National Nature Science Foundation of China (Grant No. 81603527)’. The study was partly funded by ‘The Youth Innovation Fund of the First Affiliated Hospital of Zhengzhou University’.